Fierce Critic Of Obamacare, Medicare Delivery Reforms Tapped To Run HHS

Georgia Republican Congressman Tom Price, an orthopedic surgeon and staunch opponent of Obamacare, will be nominated to be the next HHS secretary. Price has often aligned with device-industry opposition to specific Medicare reforms and payment models. President-elect Donald Trump has also tapped Seema Verma to run CMS.

Tom Price, President-elect Donald Trump's pick to run the US Department of Health and Human Services, is a Republican congressman who is an orthopedic surgeon and a staunch opponent of the Affordable Care Act (Obamacare), including the value-based purchasing models it has propelled. Trump also said he will nominate Seema Verma, a Medicaid reformer with close ties to Indiana Governor and Vice President-elect Mike Pence, to head the US Center for Medicare and Medicaid Services.

Rep. Price, R-Ga., is the chairman of the House Budget Committee and sits on the Ways and Means Committee. He...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Policy & Regulation

FDA’s AI Tool Won’t Make Regulatory Decisions, Official Says

 
• By 

Tala Fakhouri said the agency’s use of the AI tool in the review process has generated lots of questions.

MHRA Opens Second AI Airlock Program For Applications

 

"The AI Airlock program creates a supervised testing ground where novel technologies and challenge areas can be safely investigated," said James Pound, MHRA interim executive director of innovation and compliance.

Medtronic Announces Collaboration To Create A ‘New Era’ in Surgical Training

 

Medtronic is teaming up with IRCAD North America to build high-tech training and education experiences for surgeons and medical professionals in cardiovascular, neuroscience, and minimally invasive surgical specialties. The move could also further position Medtronic to seize on the growing robotics

EU Pilot Features ‘All-In-One’ Regulatory Path For Drug/Diagnostic Trials

 
• By 

The EU is testing a groundbreaking “all-in-one” process for reviewing combined drug and diagnostic trials via a single application for coordinated assessment.

More from Medtech Insight

Remepy To Embed AI In Next-Gen Digital Therapeutics For Personalized Neuroimmune Modulation

 
• By 

Remepy is exploring two potential regulatory pathways to support this strategy. The first is a combination product pathway that would formally integrate software and drug into a single therapeutic entity. The second is the FDA’s Prescription Drug Use-Related Software (PDURS) pathway.

Execs On The Move: June 9–13, 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

Medtronic Announces Collaboration To Create A ‘New Era’ in Surgical Training

 

Medtronic is teaming up with IRCAD North America to build high-tech training and education experiences for surgeons and medical professionals in cardiovascular, neuroscience, and minimally invasive surgical specialties. The move could also further position Medtronic to seize on the growing robotics